MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - mnc pharma
- NOVARTIS - MYLAN (US)
NOVARTIS vs MYLAN (US) - Comparison Results
NOVARTIS Change
Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 NOVARTIS  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| NOVARTIS Mar-19 |
MYLAN Dec-18 |
NOVARTIS/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 980 | 3,478 | - | |
| Low | Rs | 600 | 1,914 | - | |
| Sales per share (Unadj.) | Rs | 198.7 | 1,600.4 | - | |
| Earnings per share (Unadj.) | Rs | 21.0 | 43.5 | - | |
| Cash flow per share (Unadj.) | Rs | 22.3 | 343.1 | - | |
| Dividends per share (Unadj.) | Rs | 10.00 | 0 | - | |
| Dividend yield (eoy) | % | 1.3 | 0 | - | |
| Book value per share (Unadj.) | Rs | 307.5 | 1,731.4 | - | |
| Shares outstanding (eoy) | m | 24.69 | 514.50 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.0 | 1.7 | 236.0% | |
| Avg P/E ratio | x | 37.7 | 62.0 | 60.7% | |
| P/CF ratio (eoy) | x | 35.5 | 7.9 | 451.8% | |
| Price / Book Value ratio | x | 2.6 | 1.6 | 165.0% | |
| Dividend payout | % | 47.7 | 0 | - | |
| Avg Mkt Cap | Rs m | 19,508 | 1,387,238 | 1.4% | |
| No. of employees | `000 | 0.6 | 35.0 | 1.7% | |
| Total wages/salary | Rs m | 1,171 | 0 | - | |
| Avg. sales/employee | Rs Th | 8,445.4 | 23,526.5 | 35.9% | |
| Avg. wages/employee | Rs Th | 2,015.7 | 0 | - | |
| Avg. net profit/employee | Rs Th | 891.0 | 638.8 | 139.5% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 4,907 | 823,426 | 0.6% | |
| Other income | Rs m | 783 | 0 | - | |
| Total revenues | Rs m | 5,689 | 823,426 | 0.7% | |
| Gross profit | Rs m | 123 | 213,072 | 0.1% | |
| Depreciation | Rs m | 32 | 154,178 | 0.0% | |
| Interest | Rs m | 16 | 39,604 | 0.0% | |
| Profit before tax | Rs m | 858 | 19,290 | 4.4% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 340 | -3,069 | -11.1% | |
| Profit after tax | Rs m | 518 | 22,359 | 2.3% | |
| Gross profit margin | % | 2.5 | 25.9 | 9.7% | |
| Effective tax rate | % | 39.6 | -15.9 | -249.2% | |
| Net profit margin | % | 10.6 | 2.7 | 388.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 8,055 | 459,800 | 1.8% | |
| Current liabilities | Rs m | 1,850 | 335,245 | 0.6% | |
| Net working cap to sales | % | 126.4 | 15.1 | 835.9% | |
| Current ratio | x | 4.4 | 1.4 | 317.4% | |
| Inventory Days | Days | 45 | 84 | 53.9% | |
| Debtors Days | Days | 34 | 93 | 36.3% | |
| Net fixed assets | Rs m | 150 | 159,731 | 0.1% | |
| Share capital | Rs m | 123 | 438 | 28.1% | |
| Net worth | Rs m | 7,592 | 890,796 | 0.9% | |
| Long term debt | Rs m | 0 | 961,455 | 0.0% | |
| Total assets | Rs m | 9,824 | 2,389,462 | 0.4% | |
| Interest coverage | x | 54.9 | 1.5 | 3,694.7% | |
| Debt to equity ratio | x | 0 | 1.1 | 0.0% | |
| Sales to assets ratio | x | 0.5 | 0.3 | 144.9% | |
| Return on assets | % | 5.4 | 2.6 | 209.4% | |
| Return on equity | % | 6.8 | 2.5 | 271.7% | |
| Return on capital | % | 11.5 | 3.2 | 361.9% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | -1,943 | 171,108 | -1.1% | |
| From Investments | Rs m | 2,742 | -88,444 | -3.1% | |
| From Financial Activity | Rs m | -298 | -79,712 | 0.4% | |
| Net Cashflow | Rs m | 501 | 1,418 | 35.4% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 73.07 Rs / USD
Compare NOVARTIS With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare NOVARTIS With: ALKEM LABORATORIES TORRENT PHARMA PANACEA BIOTECH WOCKHARDT BIOCON
Today's Market
Bloodbath on Dalal Street: 6 Reasons Why Sensex Nosedived 1,939 Points Today(Closing)
Indian share markets witnessed a sharp sell-off today and ended deep in the red.
Related Views On News
NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)
Feb 17, 2020 | Updated on Feb 17, 2020For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
More Views on NewsMost Popular
It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Intraday Trading for a Living (Fast Profits Daily)
Feb 15, 2021In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)
Feb 16, 2021A look at what India's top equity mutual funds bought and sold in January 2021.
I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)
Feb 16, 2021Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More
